seroprevalence of epstein-barr virus among hiv positive patients moreover and its association with cd4 positive lymphocyte count.

opportunistic infections are the leading cause of hospitalization and morbidity in human immunodeficiency virus (hiv) positive patients and are the most common cause of death between them. we aimed to measure igg antibody against ebv viral capsid antigen (ebv-vca igg) to determine the seroprevalence of this infection in hiv-positive population. a case-control study between september 2011 and october 2012 was conducted in a teaching hospital enrolling 114 hiv-positive patients as case group and 114 healthy individuals as control with similar age and sex. enzyme-linked immunosurbant assay (elisa) technique was used for determination of ebv-vac igg in obtained samples. of 114 serum samples obtained from hiv-positive patients, 103 (90.4%) samples were found positive for ebv-vca igg antibody. there was no significant difference in seroprevalence of ebv vca igg antibody between patients received antiretroviral therapy and naive patients (91.5% vs. 87.5%, p>0.05). there was no statistically significant difference in ebv-vca igg seroprevalence between three groups of cd4+ in hiv positive group. in conclusion current study showed that seroprevalence of ebv in hiv-positive patients is higher than hiv-negative healthy participants; however, administration of haart and cd4+ lymphocyte count did not reveal a significant effect in seroprevalence of ebv. due to the significance of this virus in mortality and morbidity and causing certain malignancies in patients with aids, these patients are strongly recommended to be tested for this virus.